Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 20;12:2330. doi: 10.1038/s41467-021-22431-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Glucose tolerance test in cPLA2KD ^Sf1 (n = 6) and GFP^Sf1 mice (n = 6; two-way ANOVA followed by Sidak multiple comparison test, p = 0.0126 at time = 60, cPLA2KD^Sf1 vs GFP^sf1; two-tailed t test in area under the curve (AUC) during GTT, p = 0.0433, cPLA2KD^Sf1 vs GFP^sf1). b Insulin tolerance test in cPLA2KD^Sf1 (n = 6) and GFP^Sf1 mice (n = 5; two-way ANOVA followed by Sidak multiple comparison test, p = 0.0094 at time = 60 cPLA2KD^Sf1 vs GFP^sf1; two-tailed t test in AUC during GTT, p = 0.0071, cPLA2KD^Sf1 vs GFP^sf1). c Blood glucose levels after refeeding in cPLA2KD^Sf1 (n = 6) and GFP^Sf1 mice (n = 9; two-way ANOVA followed by Sidak multiple comparison test, p = 0.0255 at time = 30, p = 0.0003 at time = 60, p = 0.0211 at time = 120, cPLA2KD^Sf1 vs GFP^sf1). d 2-deoxy-glucose (2DG)-induced hyperglycemia in cPLA2KD ^Sf1 (n = 6) and GFP^Sf1 mice (n = 6). e–n Hyperinsulinemic–euglycemic clamp studies in cPLA2KD^Sf1 and GFP^Sf1 mice. e Blood glucose levels during hyperinsulinemic–euglycemic clamp studies in cPLA2KD^Sf1 or GFP^Sf1 mice. f The glucose infusion rate (GIR) required to maintain euglycemia during the clamp period in cPLA2KD^Sf1 (n = 7) or GFP^Sf1 mice (n = 7). g The average GIR between 75 and 115 min in cPLA2KD^Sf1 (n = 7) or GFP^Sf1 mice (n = 7; two-tailed t test, p = 0.0395, cPLA2KD^Sf1 vs GFP^sf1). h The rate of glucose disappearance (Rd) during the clamp period, which represents whole-body glucose utilization (two-tailed t test, p = 0.0355, cPLA2KD^Sf1 vs GFP^sf1). i The rates of whole-body glycolysis in cPLA2KD^Sf1 (n = 7) or GFP^Sf1 mice (n = 7; two-tailed t test, p = 0.0497, cPLA2KD^Sf1 vs GFP^sf1). j Endogenous glucose production (EGP) during both the basal and clamp periods in cPLA2KD^Sf1 (n = 7) or GFP^Sf1 (n = 7). k Insulin-induced suppression of EGP, which represents hepatic insulin sensitivity in cPLA2KD^Sf1 (n = 7) or GFP^Sf1 (n = 7). l–n Graphs showing 2-[¹⁴C]-Deoxy-d-Glucose uptake in red portions of the gastrocnemius (GR; l), white adipocyte (EWAT; m) and brain (cortex; n) during the clamp period in cPLA2KD^Sf1 (n = 7) or GFP^Sf1 mice (n = 7; two-tailed t test, p = 0.0352 in l, cPLA2KD^Sf1 vs GFP^sf1). o Representative micrographs showing immunofluorescent cFos staining in the hypothalamus of cPLA2KD^Sf1 and GFP^Sf1 mice after saline or glucose injection (3 g/kg). Scale bar: 500 μm. p, q Quantification of cFos expression in the dmVMH, cVMH, vlVMH, and ARC of cPLA2KD^Sf1 or GFP^Sf1 mice after saline (n = 3) or glucose (n = 3) injection (3 g/kg; VMH: two-way ANOVA followed by Sidak multiple comparison test, for dmVMH: p < 0.0001 GFP^Sf1 Sal vs GFP^Sf1 Glc, p < 0.0001 GFP^Sf1 Glc vs cPLA2KD^Sf1 Glc, for vlVMH: p < 0.0001 GFP^Sf1 Sal vs GFP^Sf1 Glc, p < 0.0001 cPLA2KD^Sf1 Sal vs cPLA2KD^Sf1 Glc. For ARC: one-way ANOVA followed by Sidak multiple comparison test, p = 0.0425 GFP^Sf1 Sal vs GFP^Sf1 Glc, p = 0.0174 cPLA2KD^Sf1 Sal vs cPLA2KD^Sf1 Glc.) All data represent the mean ± SEM; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.